Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2025-01-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于“灵康转债”预计满足转股价格修正条件的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the expected triggering of the convertible bond conversion price adjustment conditions. It details the bond code, current conversion price, relevant dates, and the regulatory framework under which the price adjustment may occur. The document includes references to previous announcements about conversion price adjustments and outlines the procedures and risks related to the potential downward adjustment of the conversion price. It is a regulatory disclosure about convertible bond terms and potential price adjustments, not a financial report, earnings release, or management discussion. The document is relatively short (2755 characters) and serves as a formal notice to investors about a possible event affecting convertible bond terms. This fits the category of a Regulatory Filing (RNS) as it is a compliance disclosure and does not contain financial statements or detailed financial analysis.
2025-01-24 Chinese
2024年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2024 annual performance forecast (业绩预告) for Lingkang Pharmaceutical Group Co., Ltd. It provides preliminary estimated financial results for the full year 2024, including net profit and revenue projections, with a clear statement that the data is unaudited and preliminary. The document explicitly states that the final accurate financial data will be disclosed in the formal 2024 annual report. The document length is short (1321 characters) and it is a forward-looking earnings forecast rather than a full financial report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights and forecasts for the fiscal year, but is not the full Annual Report (10-K) or Interim Report (IR). FY 2024
2025-01-16 Chinese
关于不向下修正“灵康转债”转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of Lingkang Pharmaceutical Group Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds ('Lingkang Convertible Bonds'). It details the triggering conditions for the price adjustment, the board's resolution, and references to previous announcements about price adjustments. The document is a regulatory announcement about convertible bond terms and board decisions, not a full financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but is a formal disclosure about capital structure and bond terms. Therefore, it fits best under 'Capital/Financing Update' (CAP). The document length is short (1774 characters), but it is substantive and not merely a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2025-01-10 Chinese
关于“灵康转债”预计满足转股价格修正条件的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the expected triggering of the convertible bond's conversion price adjustment conditions. It details the bond's basic information, the adjustment clauses, the possible triggering situation, and the company's obligations to disclose further information. The document is regulatory in nature, providing a compliance update about convertible bond price adjustments and related shareholder meeting procedures. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a full report but a regulatory announcement about a potential price adjustment event. Therefore, it fits best under Regulatory Filings (RNS). The document length is 2758 characters, which is relatively short and consistent with an announcement rather than a full report.
2025-01-03 Chinese
可转债转股结果暨股份变动公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of convertible bond conversions and related changes in share capital for Lingkang Pharmaceutical Group Co., Ltd. It details the amount of bonds converted into shares, the number of shares issued due to conversion, and the remaining unconverted bonds. The document includes specific dates and figures related to bond conversion and share capital changes. It is not a full financial report, audit, or earnings release, but rather a formal announcement of share capital changes due to convertible bond conversions. This fits the category of Share Issue/Capital Change (SHA), which covers announcements about new share issues or capital changes resulting from convertible bonds.
2025-01-03 Chinese
关于不向下修正“灵康转债”转股价格的公告
Capital/Financing Update Classification · 100% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds ('Lingkang Convertible Bonds'). It details the bond issuance, regulatory approvals, historical adjustments to the conversion price, and the recent triggering of the downward adjustment clause, followed by the board's decision not to exercise this adjustment right at this time. The document is a formal disclosure about a specific capital/financing matter related to convertible bonds and their conversion price adjustments. It is not a full financial report, earnings release, or management discussion, but rather a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short and contains substantive content about financing terms and board decisions, not merely an announcement of a report or certification.
2024-12-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.